1. Introduction {#sec1}
===============

Evidence of the first human use of plants as medicines was observed in the fossil record of the Middle Paleolithic period, which began approximately 60,000 years ago \[[@B1]\]. Traditional medical knowledge and practices developed in different civilizations by the trial-and-error use of local botanicals and other biomaterial resources that accumulated slowly over long periods of time \[[@B2]\]. The World Health Organization (WHO) estimates that herbal medicines currently serve the health needs of approximately 80% of the world\'s population, especially millions of people living in the vast rural areas of developing countries \[[@B3]\]. The Chinese have one of the oldest and distinct medical systems in the world. Traditional Chinese Medicine (TCM) has a written history of nearly 3000 years and is widely practiced in China \[[@B4]\]. China is a multiracial country with 56 nationalities, 55 of which are officially recognized as ethnic minorities in 18 provinces of China. Each ethnic minority, e.g., the Tibetans, Mongols, Uygurs, Dai, Yi, and Miao, has its own traditional medicine, and each differs slightly in theory and practice from TCM. Ethnomedicine thus refers to the use of traditional medicine guided by the medical theory and practical experience of each ethnic minority \[[@B5]\]. Since 2017, the Law of the People\'s Republic of China on Traditional Chinese Medicine has given ethnomedicine a relatively independent status although it is considered as part of TCM. The importance of ethnomedicine has been increasing in China since 1951 as discussed in detail below. *Chinese Traditional Medicine Statistics* published in 2015 by the National Administration of Traditional Chinese Medicine of China and the *Investigation and Analysis of Quality Standards of Ethnomedicines in Nine Provinces of China* published in 2015 by the National Medical Products Administration of China listed 161 pharmaceutical enterprises that produced 4317 ethnic patent medicines (EPMs) and nearly 4000 in-hospital preparations of ethnomedicines used in 253 ethnic hospitals. A total of 39 EPMs were included in *Chinese Pharmacopoeia* (2015 edition). The fourth national survey of Chinese Materia medica resources is underway with the objective of determining the status of the available resources and investigating the modern value of herbal medicine including ethnic and folk medicines \[[@B6]\]. However, the national application of ethnic medicine in China is a complex issue that involves public policy, ethnic culture, livelihood status, regional economies, the protection of wild resources, etc.

Yunnan is a multiethnic province in southwest China. In addition to the Han nationality, there are 25 ethnic minorities with a population of more than 6,000, including the Yi, Hani, Bai, Dai, Zhuang, Miao, Hui, and Tibetan. The population of ethnic minorities is estimated at over 16 million, accounting for 33.4% of the provincial total population. The Dai and Yi traditional medicine are the representatives of ethnomedicine practiced in Yunnan. Tibetan medicine as practiced in Shangri-La will be described in a subsequent review. Yunnan Province is an important pharmaceutical industry center for Dai medicine and Yi medicine. For example, Yunnan Baiyao, a highly effective patent medicine has originated from the ancient Yi prescription \[[@B5]\]. Biomedicine and public health industry have been the major industries in Yunnan since 2016, and more than 2000 ethnic medicinal resources and more than 10,000 folk prescriptions are native to Yunnan \[[@B7]\]. This review focuses on the Yi and Dai traditional medicine in Yunnan and the potential problems to be encountered in the development of policies favorable to ethnomedicine development.

2. Historical Changes of Chinese Ethnomedicine Policies {#sec2}
=======================================================

Since 1949, the Chinese government has successively introduced many policies to support and protect the development of ethnomedicine ([Table 1](#tab1){ref-type="table"}). The *Ethnic Minorities Health Work Plan of China* published in 1951 recommended that native doctors who used herbs to cure diseases should be united and supported to the greatest extent. *The Decision on Health Reform and Development* published in 1997 discussed how ethnomedicine should be mined, organized, summarized, and improved. *The Decision on Further Strengthening Rural Health Work*, published in 2002, promoted the development and organization of ethnomedicine resources and technologies in rural regions. For many years, ethnic folk doctors in rural areas provided care in very much the same way as barefoot doctors, a nickname for part-time paramedical workers in rural areas who were trained for simple diagnoses and treatments in the 1960s and 1970s. During that time, China\'s health services could not cover all areas of the country, and the need of ethnic and folk medical practices was tacitly accepted. At present, the Tibetan, Mongolian, Uygur, Dai, Kazakh, Korean, Zhuang, and Hui medicine have set up physician certification systems for special skill or knowledge to support ethnic folk doctors obtaining legal medical qualification through certain procedures. The *Outline of a Strategic Plan for Development of Traditional Chinese Medicine* (2016--2030) published by the State Council of China promotes the development of ethnomedicine.

The status of ethnomedicine in China experienced a cognitive change with the publication of the *Regulations of the People\'s Republic of China on Traditional Chinese Medicine* in 2003, which required that the administration of ethnomedicine should be implemented with compliance to the regulations that apply to TCM and established a close relationship between ethnomedicine and TCM. *The law of the People\'s Republic of China on Traditional Chinese Medicine* currently defines ethnomedicine as one part of TCM, sharing a history and development with TCM that conform to the united national culture of China. Yunnan Province has published policies and plans to regulate the development of its rich medicine resources in the autonomous prefectures of Xishuangbanna Dai, Chuxiong Yi, Diqing Tibet, Chuxiong Yi, and Xishuangbanna Dai between 2016 and 2030 \[[@B8]\].

3. Ethnic Hospitals and Pharmaceutical Enterprises in Yunnan {#sec3}
============================================================

Yunnan Province has two Yi autonomous prefectures, including Chuxiong Yi and Honghe Hani Yi, and two Dai autonomous prefectures, including Xishuangbanna and Dehong Dai Jingpo. There are also 11 Yi autonomous counties and 7 Dai autonomous counties. The Yunnan Traditional Yi Medicine Hospital, the largest Yi medical hospital in China, is located in Chuxiong City, Chuxiong Yi Autonomous Prefecture. More than 10 counties have Yi medical hospitals or outpatient departments located in villages and towns of Yunnan. Each of the two Dai autonomous prefectures has a large traditional Dai medicine hospital, the hospital of Dai traditional medicine of Xishuangbanna Dai Autonomous Prefecture and the hospital of Dai traditional medicine of Dehong Dai Jingpo Autonomous Prefecture. There are at least 6 Dai hospitals in several counties.

A total of 42 corporations are licensed to produce Dai patent medicines (DPMs) and Yi patent medicines (YPMs) in China. Two corporations are located outside Yunnan Province. Twenty corporations are in Kunming City, nine corporations are in Chuxiong Yi Autonomous Prefecture, three corporations are in Yuxi City, and two corporations are in Dali Bai Autonomous Prefecture. Wenshan City, Zhaotong City, and Xishuangbanna Dai Autonomous Prefecture have one pharmaceutical manufacturer each. The companies include the Yunnan Baiyao Group, which is best known for producing Baibaodan, the original name of Yunnan Baiyao, which was invented by Qu Huanzhang (AD 1880--1938). It also produces more than 300 other patent medicines and 19 dosage forms including Shu Lie An Capsule, Qiancao Nao Tong Oral liquid, Gu Feng Ning Capsule, Shang Yi Aerosol, Tong Shu Capsule, and Zhong Tong Liniment. In 2014, Dihon Pharmaceutical Co. was purchased by Bayer, a large German pharmaceutical company, which was marked as a significant entry for Bayer into the TCM marketplace. Dihon produces Dan E Fu Kang Ointment, Gan Dan Qing Capsule, Yu Mai Kou Yan liquid, and Wei Fu Shu Capsule.

4. Clinical Indications of Yi and Dai Medicines {#sec4}
===============================================

Based on the pharmaceutical instructions in which the properties of ethnic medicine were claimed, the clinical indications of DPMs and YPMs were surveyed and recorded, and 28 DPMs and 73 YPMs that could be approved for clinical use in China following the drug regulatory laws were identified. Fourteen DPMs such as Biao Re Qing Granule, Guan Tong Shu Oral liquid, and Hui Xue Sheng Capsule that have already been approved as over-the-counter (OTC) drugs accounted for 50% of the DPMs. The YPMs included 24 prescriptions such as Bai Bei Yi Fei Capsule, Chang Shu Zhi Xie Capsule, and Dan E Fu Kang Ointment, which have been approved as OTC drugs and account for 32.8% of the total YPMs. The information about these patent medicines is recorded in Tables [S1](#supplementary-material-1){ref-type="supplementary-material"} and [S2](#supplementary-material-1){ref-type="supplementary-material"}. As shown in [Figure 1](#fig1){ref-type="fig"}, these DPMs and YPMs are used to treat respiratory, cardiovascular, mental, and neurological diseases among others. One example is Dan Deng Tong Nao Capsule (DDTN), of which *Erigeron breviscapus* (Vaniot) Hand. -Mazz (Dengzhanxixin), a component herb, has been recorded in the pattra-leaf scripture of Dai traditional medicine for 2500 years. DDTN when combined with rehabilitation training can improve the recovery of neurological function and the quality of life of stroke patients with cerebral infarction \[[@B9]\]. DDTN is also found to prevent cerebral injury in rats with middle cerebral artery-induced ischemic stroke by decreasing the intracellular Ca^2+^ concentration and inhibiting the release of excitatory amino acids \[[@B10]\].

5. Application of Quality Standards for Yi Medicine and Dai Medicine {#sec5}
====================================================================

In China, the quality standards of ethnic medicines and their patent medicines are based on the national standards included in the *Chinese Pharmacopoeia*, which has covered ethnomedicines since 1977. Previous research on EPMs in the *Chinese Pharmacopoeia* (2015 edition) found that some traditional medicines did not establish national quality standards, and that 71 traditional medicines, which include 39 EPMs, are not listed in the *Chinese Pharmacopoeia* \[[@B11]\]. This practice (called "upside-down standards,") that involves quality standards for Chinese patent medicines (CPMs) but no standard for the composition of CPMs affects the safety of CPMs and the healthy development of the Chinese pharmaceutical industry.

The provincial standards relating to the Tibetan, the Xinjiang Uygur, the Inner Mongolia, the Guangxi Zhuang Autonomous Region, Qinghai, Sichuan, and Yunnan and Guizhou provinces also apply to the regulation of the quality of ethnic medicines in China \[[@B12]\]. The academy group and enterprise standards are also applicable to the quality of ethnomedicine. The 28 DPMs identified in the survey include 101 traditional medicines with quality standards listed in the *Chinese Pharmacopoeia* (2015 edition). The quality standards of 30 traditional medicines are listed in the Standards for Chinese medicinal materials in Yunnan Province (SYNP) or other provincial quality standards ([Figure 2](#fig2){ref-type="fig"}). Four herbal medicines including *Aristolochia chuii* Wu (Dabaijie), *Michelia mahan* C. Y. Wu (Mahan), *Asparagus officinalis* L. (Xiaobaibu), and leaf and stem of *Vitex trifolia* L. do not have applicable quality standards or are out of date. The 73 YPMs identified in the survey included 182 traditional medicines with quality standards in the *Chinese Pharmacopoeia* (2015 edition). The quality standards of 88 traditional medicines are included in the SYNP or other provincial pharmacopoeias. Eleven herbal medicines have no applicable quality standards or are out of date, including the root of *Rosa odorata* (Andr.) Sweet var. gigantea (Crép.) Rhed. Et Wils. (Gugongguo), *Fibraurea recisa* Pierre (Dahuangteng), *Dolichos falcata* Klein (Damayao), *Cyanotis arachnoidea* G. B. Clarke (Lushuicao), *Bulbophyllum reptans* (Lindl.) Lindl. (Xiaolvji), *Adenophora bulleyana* Diels (Shashen), *Cynoglossum officinale* L. (Daotihu), *Crepis lignea* (Vant.) Babc. (Wanzhangsheng), *Cymbopogon distans* (Nees) Wats. (Yunxiangcao), and Ziheche and extract of *Hemsleya chinensis Cogn*. ex Forbes et Hemsl (Xuedan extract). More information is provided in Tables [S3](#supplementary-material-1){ref-type="supplementary-material"} and [S4](#supplementary-material-1){ref-type="supplementary-material"}.

The usage frequencies of traditional medicines in DPMs and YPMs are shown in [Figure 3](#fig3){ref-type="fig"}. *Glycyrrhiza uralensis* Fisch (Gancao), *Panax notoginseng* (Burk.) F. H. Chen (Sanqi), *Angelica sinensis* (Oliv.) Diels (Danggui), *Astragalus membranaceus* (Fisch.) Bge. Var. mongholicus (Bge.) Hsiao, and *Astragalus membranaceus* (Fisch.) Bge. (Huangqi) are the most frequently used genuine medicinal materials in Yunnan Province. The other medicines included in the SYNP as Dai medicines or Yi medicines are listed in [Table 2](#tab2){ref-type="table"}.

6. Application of Medicinal Resources in Yi and Dai Medicine {#sec6}
============================================================

6.1. Botanical, Animal, and Mineral Sources of Medicines Used in DPMs and YPMs {#sec6.1}
------------------------------------------------------------------------------

Differences in geographical and climatic conditions are reflected in distinct lifestyle, customs, cultures, and usage of medicinal resources by the residents of the various regions in China. In general, botanicals are the most widely used traditional medicines. DPMs and YPMs include 361 botanical medicines, 22 animal source of medicines, and 9 mineral medicines, as shown in [Figure 4](#fig4){ref-type="fig"}. YPMs contain more animal sources of medicines than DPMs. Yi people have a long history of hunting, and many ancient documents attest to the use of animal sources of medicines. The *Yi Nationality Offering Medicine Scriptures* (Yi Zu Xian Yao Jing), written in the early Qing Dynasty, notes that up to 92.8% of the prescriptions were animal sources of medicines and were divided into 12 types including insects, meat, bones, gallbladders, fat, blood, fish gall bladders, and hair. The *Book of Good medicines for Treating Diseases* (Yi Bing Hao Yao Shu, AD.1737) describes 152 animal sources of medicines that accounted for 35.7% of Yi medicines \[[@B13]\].

Animals are therapeutic arsenals with a significant role in healing. Zootherapy are derived from products of metabolism (e.g., corporal secretions and excrements) or from nonanimal materials such as nests or cocoons \[[@B14]\]. The reasonableness of zootherapy cannot be denied, and evidence supporting their use should be strengthened by modern scientific research. The animal sources of medicines in DPMs and YPMs are listed in [Table 3](#tab3){ref-type="table"}. The use of some animal products in DPMs and YPMs is controversial, e.g., *Cordyceps sinensis*, *Moschus* deer musk, and bear bile, because these medicinal materials originate from protected wild animals or by harvesting activities that harm the ecological environment. Nevertheless, the production and use of such animal sources of medicines are restricted in China. China has joined and complied with many conventions on biological protection such as CITES (*Convention on International Trade in Endangered Species of Wild Fauna and Flora*) and the *Convention on Biological Diversity* and has implemented domestic animal protection regulations. However, the medicinal value of these and other animal sources of medicines cannot be ignored. Fortunately, substitutes are available because of the cultivation of *Cordyceps* and industrial production of artificial musk \[[@B15], [@B16]\]. Bile can be obtained from living, farmed bears but is ethically controversial \[[@B17]\]. Artificial bear bile has been reported to be effective on anticonvulsion, sedative, and choleretic \[[@B18]\].

6.2. Medicinal Parts of Botanical Medicines {#sec6.2}
-------------------------------------------

Yunnan is rich in Chinese Materia medica resources and is known as the kingdom of plants. The plant parts used in herbal medicines include seeds, berries, roots, leaves, fruits, barks, and flowers and the whole plant itself. From ancient times to the present, people have used crude botanical materials as medicines to maintain vitality and cure disease \[[@B19]\]. The medicinal parts of botanical medicines in DPMs and YPMs are shown in [Figure 5](#fig5){ref-type="fig"}. The plant parts included in DPMs and YPMs are similar, with root and rhizomes, the whole plant, and fruit and seeds being the most frequent. The various parts of the medicinal plants contain active components that are responsible for their effectiveness \[[@B20]\] and physical properties that determine their names \[[@B21]\]. For example, Huangqin (*Scutellaria baicalensis* Georgi) is called "Rijishi" in the Yi language, in which "Ri" means herbaceous plant; "Ji" means root, the medicinal part of the plant; "Shi" indicates that the color is yellow \[[@B22]\]. The continuing usage of herbal medicines prepared from wild roots and rhizomes, fruits and seeds, and whole plants is not sustainable. The best strategy for balancing industrialization and resource protection is replacing wild with cultivated resources \[[@B23]\].

7. Rare and Endangered Medicinal Materials {#sec7}
==========================================

The rapidly increasing demand for CPMs is likely to challenge the sustainability of herbal resources in China. At present, 80% of the most frequently used species cannot meet medical demand, and 1,800--2,100 medicinal species are facing extinction \[[@B24]\]. In the *China Plant Red Data Book* published in 1992, 388 plant species were listed as threatened, with 121 species as endangered and needing first-grade national protection, 110 species as rare needing second-grade national protection, and 157 species as vulnerable needing third-grade national protection. Of those plant species, 77 are herbal medicines that account for 19.86% of the threatened species \[[@B25]\]. The national key protection name list of wild animals in China includes 257 animal sources. The shortage of medicinal plants available to pharmaceutical companies can be partially reduced by the cultivation of at least 200 herbs, while some special herbs used in ethnomedicine are obtained by continuous wild collection without planned scientific cultivation. The rare medicinal materials used in DPMs and YPMs are listed in [Table 4](#tab4){ref-type="table"}.

Those plants are protected by the Chinese government and some international nongovernment organizations such as the International Union for Conservation of Nature. *Cistanche deserticola* Y. C. Ma (Rouchongrong), *Panax ginseng* C. A. Mey (Renshen), *Glycyrrhiza aponic* Bat (Gancao), or other rare medicinal materials listed in the catalogs is protected and utilized sustainably in China. However, the number of endangered ethnic-specific medicines is far larger than that recorded in the catalogs; for example, more than 3000 tons of *Rodgersia sambucifolia* Hemsl. (Yantuo) are collected annually to produce YPMs. The availability of wild *Rodgersia* plants is sharply reduced, and resources are severely damaged in Luquan, Yongsheng, Yulong, Heqing, and Ninglang counties of Yunnan Province \[[@B26]\], while its cultivation research just began in recent years. [Figure 6](#fig6){ref-type="fig"} shows the planting situation of *Rodgersia sambucifolia* Hemsl. in the Meizi test ground, which is subordinate to the Institute of Alpine Economics and Botany, Yunnan Academy of Agricultural Sciences. Consequently, 30 traditional medicines have been listed in the *Rare Traditional Chinese Herbs of Yunnan Province in Urgent Needs* (RTCHYN), and those used in DPMs and YPMs are shown in [Table 5](#tab5){ref-type="table"} \[[@B27]\].

Medicines with pharmacological activities that are present in traditional ethnomedicine are likely to be clinically useful, but they may also be toxic, especially if used incorrectly or in the wrong amounts. Unlike that for modern drugs, the efficacy and toxicity assessments of these ethnomedicines are based on traditional knowledge and clinical experience rather than on laboratory evaluation \[[@B28]\]. Toxicity associated with the use of Chinese ethnomedicine may occur because of the environment, religious beliefs, or medical practices. The *Chinese Pharmacopoeia* includes 83 traditional medicines that are considered toxic \[[@B29]\]; some medicines listed in provincial standards of herbal medicines are also considered toxic \[[@B30]\].

Ten toxic medicines are used in 11 DPMs; six of those are included in the *Chinese Pharmacopoeia* (2015 edition) and four toxic medicines in the SYNP. One toxic medicine is used in Dai traditional medicine, and two toxic medicines are used in Yi traditional medicine. The 40 YPMs include 24 toxic herbs; 12 toxic medicines are in the *Chinese Pharmacopoeia* (2015 Edition) and 12 are in the SYNP. Four medicines are known as Yi medicines. Although some toxic ethnomedicines are used in DPMs and YPMs, the proprietary medicines are considered safe and approved for use in China because pharmaceutical processing, combining, and decocting contribute to reducing toxicity and enhancing efficacy. In the traditional Dai medicine (TDM), "YaGei" herbs are used to reduce toxicity. The "YaGei" detoxification theory is a unique supplement of TDM \[[@B31]\], and "YaGei" medicines are used as antidotes to relieve adverse reactions caused by food poisoning, drug poisoning, and other substances \[[@B32]\]. Dai people consume antidotes regularly to eliminate the microtoxins from the body, reduce the chance of illness, and prolong life.

Due to the lack of more pharmaceutical information disclosed, as well as the lack of basic research, the safety information of these DPMs and YPMs including toxic medicines is insufficient. The modern toxicological evidence of these toxic medicines is collected and summarized in Tables [6](#tab6){ref-type="table"} and [7](#tab7){ref-type="table"}, focusing on Dai and Yi toxic medicines. The root of *Tripterygium hypoglaucum* (Levl.) Hutch (Huobahuagen) soaked in wine as an oral medicine is an ancient Yi medicine described in the *Ailao Materia Medica* in the treatment of arthritis, joint swelling, pain, bruises, and sprains \[[@B59]\]. *Boenning hauseniase silicarpa* Levl. (Shijiaocao) is described in the *Materia Medica in South Yunnan* (Dian Nan Ben Cao, AD.1396 -1476) written by Lan Mao as a bitter, pungent, and warm medicine used to treat chest pain, heartache, stomachache, and abdominal distension. Shijiaocao is also described in the *Ailao Materia Medica* as a treatment for sore throat, gastric pain, and dysentery. It is described as a cure of acute gastroenteritis in combination with the parasite of *Zanthoxylum bungeanum* in the *Wa Die Yi Medical Book*, which was written at the end of the Qing Dynasty \[[@B60]\]. Ancient documents describe the usage of the toxic herbs included in the medical practice of Yi, Dai, or other ethnic minorities in Yunnan. Modern toxicological study can ensure their safe and effective use, and further study is warranted to determine how the toxicity reduces while the prescription remains effective.

8. Concluding Remarks {#sec8}
=====================

Ethnomedicine is an important part of TCM that has a unique medical theoretical system and refers to a wide range of healthcare systems/structures, practices, beliefs, and therapeutic techniques that arise from indigenous cultural development. Thousands of years of ethnic amalgamation has produced diversity, integration, and differences among the traditional medicine of different Chinese ethnics. Approximately 8, 000 medicinal species are used by 40 ethnic minorities in China, which account for over 70% of the Chinese Materia medica resources. Data from the National Medical Products Administration of China show that there are more than 600 types of EPMs \[[@B12]\]. The *Chinese Pharmacopoeia* (1977 edition) began to cover DPMs, and some Miao patent medicines and YPMs were collected from the 2015 edition of *Chinese Pharmacopoeia*. Overall, a total of 39 CPMs were identified as EPMs, 26 EPMs as prescription drugs, and 13 EPMs as OTC drugs \[[@B11]\]. Prescriptions that are not approved by the government were not included in the review evaluated, but are still in use in clinics in regions of China inhabited by ethnic groups.

This review focuses on Dai and Yi traditional medicines in Yunnan Province because of their long histories and descriptions in the ancient medical literature. The earliest book of Yi traditional medicine that can be verified is the *Yuanyang Yi Medicine Book*, which was written in 957 AD and found in Yuanyang County of Yunnan Province in 1985 \[[@B14]\]. The earliest books of Dai traditional medicine that can be verified are *Ge Ya San Ha Ya*, which was written in 964-884 BC, and *Dang Ha Ya Long*, which was written in 1323 AD \[[@B61]\]. There are 1, 666 Dai medicines \[[@B62]\], nearly 1, 400 Yi medicines \[[@B13]\], and 400 medicines are listed in the *Yi Materia Medica* \[[@B63]\]. There are 478 Yi medical formulas described in *Chinese Yi Medicine Prescriptions Science* \[[@B64]\], and 200 Dai medical formulas are in *Study on Dai classical prescriptions of China* \[[@B65]\]. The numbers of folk formulas from Dai and Yi traditional medicine are not available to record yet. Just as the example of Yunnan Baiyao mentioned before, a series of ethnomedicines in Yunnan were successfully industrialized and modernized to promote the modern vitality of ancient ethnomedicines and thus serve a wide population range. The Tong Shu Capsule is a YPM produced by the Yunnan Baiyao Group that has been approved recently for phase II clinical research in the United States. Yunnan Province expects to produce TCMs including ethnomedicines with a value of 140 billion RMB in 2020 and an average annual growth of more than 15%, accounting for 75% of its production \[[@B65]\].

Five key conclusions can be drawn from this investigation of Dai and Yi medicines.

First, except for the Yunnan Baiyao Group and the Dihon Pharmaceutical Company, most of the pharmaceutical manufacturers of EPMs in Yunnan Province are small enterprises, thereby limiting research and development capacity. A search on the *China National Knowledge Infrastructure* (CNKI, <http://www.cnki.net>) found 163 articles that reported investigations of these 28 DPMs reviewed here and 59 articles about Yunnan Baiyao Aerosol, whereas it is only one of the CPMs produced by the Yunnan Baiyao Group. In 2015, 100 million bottles of Yunnan Baiyao Aerosol were produced, with a value of more 1.5 billion RMB. In the same year, the overall sales revenue of the Yunnan Baiyao Group was 20.74 billion RMB \[[@B7]\].

Second, the sale volumes of YPMs and DPMs cannot be grasped, and it is hard to determine the extent to which traditional medicines used in YPMs and DPMs are collected in the wild. This will be a challenge to sustainable utilization for Chinese Materia medica resources.

Third, the use of toxic medicine used in ethnomedicine is of concern. Herbal medicine containing aristolochic acid has been associated with nephropathy in Belgium \[[@B66]\], and the adverse events associated with the use of Xiao Chaihu Tang in Japan \[[@B67]\] have led to warnings of the safety of CPM. Scientific evidence is needed to demonstrate the rationale and necessity of using toxic herbs in EPMs.

Fourth, the identification and usage of traditional medicines vary among ethnic minorities because of differences in experiences of clinical practice. The survey of DPMs and YPMs showed the differences in the number of animal sources of medicines used by the Yi and Dai people. The differences were also found in the ancient medical literature of Yi and Dai minorities.

Fifth, Dai and Yi medical prescriptions were traditionally written in the Dai and Yi languages, but the current clinical indications of DPMs and YPMs are written in Chinese. Difficulties in translation have hampered evaluation of how these ethnic medicines are used. Efforts to obtain accurate translations will be the next important work.

The sale volumes of DPMs and YPMs are not available because they belong to trade secrets. Because the descriptions of ethnic medical prescriptions in the ancient literature were written in Yi and Dai languages, they are hard to comprehend. However, the medical practices and culture of ethnic minorities have existed in Yunnan for thousands of years and have resulted in written records of more than 1300 ethnic medicinal materials and nearly 30,000 folk prescriptions. The medical information has been passed on orally or via ancient documents written in various ethnic minority languages such as the *San Ma Tou Yi Medical Book* and the *Lao Wu Dou Yi Medical book* written in the late Qing Dynasty of China. The ongoing scientific investigation and sustainable utilization of medicine resources will help to increase the impact of ethnomedicines of Yunnan Province on improvement of human health.
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Tables S1 and S2: in this article, all the ethnic patent medicines (EPMs) produced in Yunnan Province were collected. The information of these EPMs is obtained from the National Medical Products Administration of China, and all EPMs listed in the article have been checked according to open drug instructions. Table S1 and Table S2 provide the following information including the drug name, Chinese name, approval number, clinical indications, dosage form, and prescription status of Yi patent medicines (YPMs) and Dai patent medicines (DPMs). Some of these data supported the results of "clinical indications of Yi and Dai medicines" and Figure 1 in this article. Tables S3 and S4: in this article, the investigation focused on the composition of each EPM, the types of medicinal resources and medicinal parts, and quality standards for medicinal materials used in EPMs, including botanical, animal, and mineral resources. All these data are listed as two tables, showing separately the composition information and quality standards in DPMs (Table S3) and YPMs (Table S4). The information includes the drug name and pinyin name, Chinese name, scientific name, and medicinal parts of medicinal materials used in EPMs, and also contains the quality standard information of medicinal materials which can be regarded as the most important key supporting data for this article.
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![Clinical indications of DPMs and YPMs. DPMs, Dai patent medicines; YPMs, Yi patent medicines.](ECAM2020-1023297.001){#fig1}

![Quality standards of herbal medicines in DPMs and YPMs. ChP, *China Pharmacopoeia*; SYNP, Standards for Chinese medicinal materials in Yunnan Province; SPOP, Standards for Chinese medicinal materials in other province except Yunnan; NQS, No quality standard.](ECAM2020-1023297.002){#fig2}

![Usage frequencies of herbal medicines in DPMs and YPMs. DPM, Dai patent medicine; YPM, Yi patent medicine; Gancao, *Glycyrrhiza glabra* L. or *Hemsleya chinensis Cogn*.ex Forbes et Hemsl (Xuedan extract; Sanqi, *Panax notoginseng* (Burk.) F. H. Chen; Danggui, *Angelica sinensis* (Oliv.) Diels; Huangqi, *Astragalus propinquus* Schischkin; Jishiteng, *Paederia scandens* (Lour.) Merr.; Dengzhanxixin, *Erigeron breviscapus* (Vaniot) Hand. -Mazz; Sharen, *Amomum villosum* Lour.; Huzhang, *Polygonum cuspidatum* Sieb.et Zucc.; Jinqiaomai, *Fagopyrum dibotrys* (D. Don) Hara; Chonglou, *Paris polyphylla* Smith var. chinenisi (Franch) Hara; Gonglaomu, *Mahonia bealei* (Fort.) Carr.; Dahongpao, *Campylotropis hirtella* (Franchet) Schindler; Gegen, *Pueraria lobata* (Willd.) Ohwi; Zidanshen, *Salvia yunnanensis* C. H. Wright; Chuangxiong, *Ligusticum chuanxiong* Hort.; Chaihu, *Bupleurum scorzonerifolium* Willd; Yanhusuo, *Corydalis yanhusuo* W. T. Wang; Zhizi, *Gardenia jasminoides* Ellis; Baiji, *Bletilla striata* (Thunb.) Reichb. f.; Chenpi, *Citrus japonica* Blanco; Honghua, *Carthamus tinctorius* L.](ECAM2020-1023297.003){#fig3}

![The use of botanical, animal, and mineral resources in DPMs and YPMs. DPMs, Dai patent medicines; YPMs, Yi patent medicines.](ECAM2020-1023297.004){#fig4}

![Relative contribution of the parts of medicinal plants to DPMs and YPMs.](ECAM2020-1023297.005){#fig5}

![*Rodgersia sambucifolia* Hemsl. cultivated in the Meizi test ground (Lijiang, Yunnan). Toxic medicines used in DPMs and YPMs.](ECAM2020-1023297.006){#fig6}

###### 

History of Chinese ethnomedicine policy.

  Time   Policy outline                                                                   Promulgator
  ------ -------------------------------------------------------------------------------- ---------------------------------------------
  1951   Ethnic minorities health work plan of China                                      Unknown
  1984   Several opinions on strengthening ethnic minorities work                         Ministry of Health and NEAC
  1997   Decision on health reform and development                                        CPC Central Committee and the State Council
  2002   Decision on further strengthening rural health work                              CPC Central Committee and the State Council
  2003   Regulations of the People\'s Republic of China on traditional Chinese medicine   The State Council
  2007   Guiding opinions on strengthening the development of ethnomedicine               11 ministries including NATCM
  2017   The law of the People\'s Republic of China on traditional Chinese medicine       NPC standing committee
  2018   Some opinions on strengthening the ethnomedicine work in the new era             13 ministries including NATCM

NEAC: National Ethnic Affairs Commission of PRC (China); CPC Central Committee: the Central Committee of the Communist Party; NATCM: National Administration of Traditional Chinese Medicine of PRC (China); NPC: National People\'s Congress.

###### 

Traditional medicines used in DPMs and YPMs and listed in the SYNP.

  No   Scientific name                                                   Pinyin name           MP                            EM    Frequency
  ---- ----------------------------------------------------------------- --------------------- ----------------------------- ----- -----------
  1    *Plumbago zeylanica* Linn.                                        Baihuadan             Stem and leaf                 Yi    1
  2    *Toddalia asiatica* (L.) Lam.                                     Feilongzhangxue       Stem                          Yi    1
  3    *Tripterygium hypoglaucum* (Levl.) Hutch                          Huobahuagen           Root                          Yi    3
  4    *Inula cappa* (Buch -Ham) DC.                                     Yang\'erju            Whole plant                   Yi    2
  5    *Geum aleppicum* Thumb. var. Chinese Bolle                        Wuqihuanyangcao       Whole plant                   Yi    3
  6    *Rhodobryum giganteum* (Hook.) Par.                               Huixincao             Whole plant                   Yi    2
  7    *Polygonum paleaceum* Wall. ex Hook.                              Caoxuejie             Rhizome                       Yi    2
  8    *Polygala arillata* Buch. Ham. ex D. Dom                          Jigen                 Roots and rhizome             Yi    1
  9    *Salvia yunnanensis* C. H. Wright                                 Zi Danshen            Root                          Yi    6
  10   *Ampelopsis delavayana* (Franch.) Planch.                         Yuputao gen           Root                          Yi    3
  11   *Swertia patens* Burk.                                            Xiao\'er futong cao   Whole plant                   Yi    3
  12   *Polygonum cuspidatum* Sieb.et Zucc.                              Huzhangye             Leaf                          Yi    1
  13   *Cynodon dactylon* (L.) Pers.                                     Qianxiancao           Whole plant                   Yi    1
  14   *Potentilla fulgens* Wall. ex Hook                                Guanzhong             Root                          Yi    2
  15   *Ainsliaea pertyoides* Franch. var. albo-tomentosa Beauv.         Yexiahua              Whole plant                   Yi    1
  16   *Valeriana jatamansi* Jones                                       Matixiang             Roots and rhizome             Yi    1
  17   *Speranskia tuberculata* (Bunge) Baillon                          Tougucao              Aerial part                   Yi    3
  18   *Arthromeris mairei* (Brause) Ching                               Diwugong              Rhizome                       Yi    1
  19   *Schefflera venulosa* (Wight et Arn.) Harms                       Qiyelian              Whole plant, stem, and leaf   Yi    3
  20   *Boenninghausenia sessilicarpa* Levl.                             Shijiaocao            Whole plant                   Yi    2
  21   *Oxalis corniculata* Linn.                                        Zajiacao              Whole plant                   Yi    1
  22   *Anemone rivularis* Buch. Ham. ex DC.                             Huzhangcao            Root                          Yi    2
  23   *Opuntia stricta* (Haw.) Haw. var. dillenii (Ker Gawl.) Benson.   Xianrencao            Stem                          Yi    1
  24   *Dysosma versipellis* (Hance) M. Cheng ex Ying                    Bajiaolian            Rhizome                       Yi    4
  25   *Jatropha curcas* L.                                              Gaotong               Root bark, stem bark          Yi    1
  26   *Ficus tikoua* Bur.                                               Dibanteng             Cane                          Yi    1
  27   *Kadsura longipedunculata* Finet et Gagnep.                       Wuxiangxueteng        Cane                          Yi    3
  28   *Leycesteria aponic* Wall. var. stenosepala Rehd.                 Dazuifeng             Aerial part                   Yi    1
  29   *Anaphalis bulleyana* (J. F. Jeffr.) Chang                        Wuxiangcao            Whole plant                   Yi    1
  30   *Craibiodendron yunnanense* W.W. Smith                            Jinyezi               Leaf                          Yi    1
  31   *Phyllanthus urinaria* L.                                         Yexiazhu              Aerial part                   Dai   2
  32   *Brassica integrifolia* (West) O. E. Schulz ex Urb.               Kucaizi               Seed                          Dai   1
  33   *Zingiber purpureum* Rosc.                                        Zisejiang             Rhizome                       Dai   1
  34   *Polyrhachis dives* Smith                                         Weimayi               Body                          Dai   4
  35   *Phyllanthus niruri* L.                                           Zhuzicao              Whole plant                   Dai   1
  36   *Tacca chantrieri* Andre                                          Jiangenshu            Stem tuber                    Dai   2
  37   *Stephania epigaea* H. S. Lo                                      Diburong              Root tuber                    Dai   1
  38   *Streptocaulon juventas* (Lour.) Merr.                            Tengkushen            Root                          Dai   1
  39   *Inula cappa* (Buch.-Ham) DC                                      Yangerjugen           Root                          Dai   1
  40   *Benincasa hispida* (Thunb.) Cogn.                                Kudonggua             Fruit                         Dai   1

DPMs, Dai patent medicines; YPMs, Yi patent medicines; SYNP, Standards for Chinese medicinal materials in Yunnan Province; MP, medicinal parts; EM, ethnic medicine.

###### 

Medicinal sources from the animals used in DPMs and YPMs that are listed in the SYNP.

  Scientific name                        Pinyin name       MP                             Standard   DPM   YPM
  -------------------------------------- ----------------- ------------------------------ ---------- ----- -----
  *Cervus nip port* Temminck             Lurong            Antler                         ChP        1     0
  *Cryptotympana pustulata* Fabricius    Chantui           Slough                         ChP        2     0
  *Gallus gallus domesticus* Brisson     Jineijing         Gizzard                        ChP        1     1
  *Polyrhachis dives* Smith              Heimayi           Body                           SYNP       1     4
  *Gekko gecko* Linnaeus                 Gejie             Body                           ChP        0     4
  *Pheretima aspergillum* (E. Perrier)   Dilong            Body                           ChP        0     4
  *Bufo bufo gargarizans* Cantor         Chansu            Secretion                      ChP        0     1
  *Aspongopus chinensis* Dallas          Jiuxiangchong     Body                           ChP        0     2
  Selenarctos thibetanus Cuvier          Xiongdanfen       Bile                           SYNP       0     1
  *Bombyx mori* Linnaeus                 Jiangchan         Body                           ChP        0     1
  *Periplaneta japonica* Linnaeus        Feilie            Body                           SYNP       0     1
  *Sepiella maindroni de* Rochebrune     Haipiaoqiao       Shell                          ChP        0     1
  *Moschus berezovskii* Flerov           Shexiang          Secretion                      ChP        0     1
  *Armadillidium vulgare* Latreille      Shufuchong        Body                           SSDP       0     2
  *Cervus nip port* Temminck             Lujiaoshuang      Antler colloid                 ChP        1     1
  *Cordyceps sinensis* (BerK.) Sacc.     Dongchongxiacao   Bacterial and insect complex   ChP        2     2

EPM, ethnic patent medicine; MP, medicinal parts; ChP, *Chinese Pharmacopoeia*; SSDP, Standards for Chinese medicinal materials in Shandong Province (2012).

###### 

Rare medicinal materials used in DPMs and YPMs.

  Herbal name                                                       Scientific name                                            NPWP   IUCN              Proprietary       NPWM   UF
  ----------------------------------------------------------------- ---------------------------------------------------------- ------ ----------------- ----------------- ------ ----
  Gancao                                                            *Glycyrrhiza uralensis* Fisch                              II     LC                ---               II     26
  *Glycyrrhiza inflata* Bat.                                        II                                                         LC     ---               II                       
  *Glycyrrhiza glabra* L.                                           II                                                         LC     ---               II                       
  Renshen                                                           Panax *ginseng* C. A. Mey                                  I      CR                ---               II     4
  Lianqiao                                                          *Forsythia suspense* (Thunb.) Vahl.                        ---    ---               ---               III    4
  Huangqin                                                          *Scutellaria baicalensis* Georgi                           ---    ---               ---               III    4
  Wuweizi                                                           *Schisandra chinensis* (Turcz.) Baill.                     II     LC                ---               III    1
  Lurong                                                            *Cervus nip port* Temminck                                 ---    ---               ---               I      1
  *Cervus elaphus* Linnaeus                                         ---                                                        ---    ---               I                        
  Rouchongrong                                                      *Cistanche deserticola* Y. C. Ma                           II     EN                ---               III    1
  *Cistanche tubulosa* (Schenk) Wight                               II                                                         ---    ---               ---                      
  Huangbai                                                          *Phellodendron chinense* Schneid                           ---    ---               ---               II     2
  Duzhong                                                           *Eucommia ulmoides* Oliv.                                  ---    ---               ---               II     1
  Longdan                                                           *Gentiana manshurica* Kitag.                               ---    ---               ---               III    3
  *Gentiana scabra* Bge                                             ---                                                        ---    ---               III                      
  *Gentiana triflora* Pall.                                         ---                                                        ---    ---               III                      
  *Gentiana regescens* Franch.                                      ---                                                        ---    ---               III                      
  Huanglian                                                         *Coptis chinensis* Franch                                  ---    ---               Unique to China   II     1
  *Coptis deltoidea* C. Y. Cheng et Hsiao                           ---                                                        VU     Unique to China   II                       
  *Coptis teetoides* C. Y. Cheng.                                   ---                                                        ---    ---               II                       
  Houpu                                                             *Magnolia officinalis* Rehd. et Wils                       II     NT                Unique to China   II     1
  *Magnolia officinalis* Rehd. et Wils. var. biloba Rehd. et Wils   II                                                         ---    Unique to China   II                       
  Huangbai                                                          *Phellodendron chinense* Schneid                           ---    ---               ---               II     2
  Zicao                                                             *Arnebia euchroma* (Royle) Johnst                          ---    ---               ---               III    1
  Qingjiao                                                          *Gentiana macrophylla* Pall.                               ---    ---               ---               III    1
  *Gentiana macrophylla* Maxim.                                     ---                                                        ---    ---               III                      
  *Gentiana crassicaulis* Duthie ex Burk.                           ---                                                        ---    ---               III                      
  *Gentiana dahurica* Fisch                                         ---                                                        ---    ---               III                      
  Shexiang                                                          *Moschus berezovskii* Flerov.                              ---    ---               ---               II     1
  *Moschus sifanicus* Przewalski.                                   ---                                                        ---    ---               II                       
  *Moschus moschiferus* Linnaeus.                                   ---                                                        ---    ---               II                       
  Chonglou                                                          *Paris polyphylla* Smith var. *chinensis* (Franch.) Hara   II     ---               ---               ---    7

NPWP, National Key Protected Wild Plants of China (August 4, 1999); NPWM, National Key Protected Species of Wild Medicinal Materials of China (Dec. 1, 1987); IUCN, International Union for Conservation of Nature (CR, critically endangered; LC, least concern; EN, endangered; VU, vulnerable; NT, near threatened); UF, usage frequency in DPMs and YPMs.

###### 

Traditional medicines listed in the RTCHYN.

  Scientific name                                                                          Pinyin name       Medicinal parts                Regional distribution^*∗*^                                                            Standard   UF
  ---------------------------------------------------------------------------------------- ----------------- ------------------------------ ------------------------------------------------------------------------------------- ---------- ----
  *Erigeron breviscapus* (Vaniot) Hand. -Mazz.                                             Dengzhanxixin     Whole plant                    Areas except southwest of Yunnan                                                      ChP        7
  *Cordyceps sinensis* (BerK.) Sacc.                                                       Dongchongxiacao   Bacterial and insect complex   Deqin, Shangri-La, Lijiang, Binchuan, Lvfeng, Guangtong                               ChP        4
  *Dracaena cochinchinensis* (Lour.) S. C. Chen A                                          Longxuejie        Resin                          Jinping, Menglian, Pu\'er, Jinghong, Zhenkang                                         SGZP       2
  *Cyanotis arachnoidea* C. B. Clarke                                                      Lushuicao         Whole plant                    Menghai, Menglian, Jinghong, Jingdong, Mengzi, Anning, Kunming, Pingbian              No         1
  *Swertia mileensis* T. N. He et W. L. Shi                                                Qingyedan         Whole plant                    Mile                                                                                  ChP        2
  *Anisodus acutangulus* C. Y. Wu et C. Chen                                               Sanfensan         Roots                          Lijiang                                                                               SYNP       1
  *Hemsleya amabilis* Diels                                                                Xuedan            Roots                          Kunming, chongming, Binchuan, Eryuan, Dali, Heqing                                    No         1
  *Bergenia purpurascens* (Hook.f.et Thoms.) Engl. var. delavayi (Franch.) Engl. et Irm.   Yanbaicai         Rhizome                        Deqin, Weixi, Shangri-La, Lijiang, Dali, Qujing, Ludian, Zhaotong, Gongshan, Fugong   ChP        1

RTCHYN, *Rare Traditional Chinese Herbs of Yunnan Province in Urgent Needs*. ^*∗*^Regional distribution is from the *Flora of Yunnan* (*Science Press of China*, 2006). UF, usage frequency; ChP, *Chinese Pharmacopoeia*; SGZP, Standards for Chinese medicinal materials in Guizhou Province (2009); SYNP, Standards for Chinese medicinal materials in Yunnan Province (2005).

###### 

Toxic medicines in DPMs.

  Scientific name                                           Pinyin name     Toxicity degree   Standard   DPM       Modern toxicology                                                                                                                                                                                                      References
  --------------------------------------------------------- --------------- ----------------- ---------- --------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------
  *Paris polyphylla* Smith var. *chinensis* (Franch) Hara   Chonglou        LT                ChP        RBQC      Toxic to the digestive system and has cardio toxicity and neurotoxicity, LD~50~ = 2.68 g/kg (mice, p.o.)                                                                                                               \[[@B33]\]
  *Curculigo orchioides* Gaertn.                            Xianmao         MT                ChP        LXBST     LD~50~ = 215.9 g/kg (ethanol extract, rats, p.o.) and damages the liver, kidney, and reproductive organs with oral administration of 120 g/kg (ethanol extract, rats, 6 months)                                        \[[@B34]\]
  *Cnidium monnieri* (L.) Cuss.                             Shechuangzi     LT                ChP        LXBST     Nausea and vomiting, decreased spontaneous activity, shortness of breath, unstable gait, and tremor (ethanol extract), LD~50~ = 17.45 g/kg (mice, p.o.), MTD = 1.50 g/kg, or LD~50~ = 3.45 g/kg (osthol, mice, p.o.)   \[[@B35]--[@B37]\]
  *Zanthoxylum nitidum* (Roxb.) DC.                         Liangmianzhen   LT                ChP        7-JDHXO   Nitidine chloride damages the liver and kidney cells and decreases the heart rate of zebrafish                                                                                                                         \[[@B38]\]
  *Pinellia ternate* (Thunb.) Breit.                        Banxia          MT                ChP        SBZKG     LD~50~ = 42.7 ± 1.27 g/kg (mice, p.o.), damages the renal and liver, causes serious damage to gastric mucosa, and has significant toxicity on pregnancy maternal mice and embryo (total alkaloids)                     \[[@B39]\]
  *Prunus armeniaca* L. var. *ansu* Maxim                   Kuxinren        LT                ChP        SBZKG     LD~50~ of amygdalin is 25 g/kg (mice, i.v.), 887 mg/kg (mice, p.o.) and hydrocyanic acid produced by amygdalin inhibits the activity of cytochrome oxidase, leading to cell respiration inhibition and cell death      \[[@B40]\]
  *Plumbago zeylanica* Linn.                                Bhuadan         LT                SYNP       DLBSC     Skin redness, swelling, and peeling when contacted and antiovulation activities for female rats (alcohol extract)                                                                                                      \[[@B41], [@B42]\]
  *Tacca chantrieri* Andre                                  Jiangenshu      MT                SYNP       YGT       Diarrhea and vomiting in mild intoxication and intestinal mucosal exfoliation and hemorrhoea appear in severe poisoning patients                                                                                       \[[@B43]\]
  *Tripterygium hypoglaucum* (Levl.) Hutch                  Huobahuagen     LT                SYNP       GTSL      LD~50~ = 79 g/kg (male mice, p.o.), LD~50~ = 100 g/kg (female mice, p.o.), and reversible antifertility effect                                                                                                         \[[@B44], [@B45]\]
  *Erythrina variegata* L. var. orientalis (L.) Merr        Haitongpi       MT                SSCP       GTSL      Unknown                                                                                                                                                                                                                 

HT, high toxicity; MT, medium toxicity; LT, low toxicity; SSCP, Standards for Chinese medicinal materials in Sichuan Province (2010); SYNP, Standards for Chinese medicinal materials in Yunnan Province (2005); RBQC, Ru Bi Qing Capsule; LXBST, Lu Xian Bu Shen Tablet; 7-JDHXO, 7-Jie Du Huo Xue Ointment; SBZKG, Shen Bei Zhi Ke Granular; DLBSC, Dan Lv Bu Shen Capsule; YGT, YaGei Tablet; GTSL, Guan Tong Shu Oral liquid.

###### 

Toxic medicines in YPMs.

  Scientific name                                                               Pinyin name        Toxicity degree   Standard   YPM                         Modern toxicology                                                                                                                                                                                                        References
  ----------------------------------------------------------------------------- ------------------ ----------------- ---------- --------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ --------------------
  *Paris polyphylla* Smith var. *chinensis* (Franch) Hara                       Chonglou           LT                ChP        GFNC, NQSG, SYA, TSC, ZTL   ---                                                                                                                                                                                                                      ---
  *Osmunda japonica* Thunb.                                                     Ziqiguanzhong      LT                ChP        SWYA                        Unknown                                                                                                                                                                                                                  ---
  *Evodia rutaecarpa* (Juss.) Benth.                                            Wuzhuyu            LT                ChP        GDQC, HWYP                  LD~50~ is 2.70 mL/kg (volatile oil, mice, p.o.), one of the main target organ is the liver                                                                                                                               \[[@B46]\]
  *Bufo bufo gargarizans* cantor                                                Chansu             MT                ChP        CLTC                        Ventricular arrhythmias and increasing the levels of Ca^2+^, CK, and LDH in the heart                                                                                                                                    \[[@B47]\]
  *Artemisia argyi* Levl. Et Vant.                                              Aiye               LT                ChP        KSG                         LD~50~ is 80.2 g/kg (aqueous extract, mice, p.o.), LD~50~ is 1.67 mL/kg (volatile oil, mice, p.o.), MTD is 75.6 g/kg (ethanol extract, mice, p.o.)                                                                       \[[@B48]\]
  *Aconitum kusnezoffii* Reichb.                                                Caowu              HT                ChP        TXT                         Causing serious cardiac dysfunction and damaging the nervous system. LD~50~ is 1.8 mg/kg, (aconitine, mice, p.o.), LD~50~ is 5.8 mg/kg (hypaconitine, mice, p.o.), and LD~50~ is 1.9 mg/kg (mesaconitine, mice, p.o.).   \[[@B49], [@B50]\]
  *Papaver somniferum* L.                                                       Yingsuqiao         MT                ChP        KLT                         Main toxic components are morphine and codeine. Morphine with 60 mg causes poisoning and 250 mg leads to death                                                                                                           \[[@B51]\]
  *Arisaema erubescens* (Wall.) Schott.                                         Tiannanxing        MT                ChP        TXT                         Producing folate deficiency and injury to the kidneys                                                                                                                                                                    \[[@B52]\]
  *Laggera pterodonta* (DC.) Benth.                                             Choulingdan        MT                ChP        LL, SKCG                    LD~50~ is 1.19 g/kg (water extract, mice, i.p.)                                                                                                                                                                          \[[@B53]\]
  *Prunus armeniaca* L. var. *ansu* Maxim                                       Kuxinren           LT                ChP        SKCG, CLTC                  ---                                                                                                                                                                                                                      ---
  *Pinellia ternate* (Thunb.) Breit                                             Banxia             MT                ChP        WFSC, ZXASG                 ---                                                                                                                                                                                                                      ---
  *Psammosilene tunicoides* W. C. Wu et C. Y. Wu                                Jintiesuo          LT                ChP        ZTL                         LD~50~ is 4.8471 (mice, p.o.) and toxic target organs include the lungs, spleen, and stomach                                                                                                                             \[[@B54]\]
  *Boenninghausenia sessilicarpa* Levl.                                         Shijiaocao         LT                SYNP       SAC, SKCG                   The ether extract reduces the activity in mice by intraperitoneal injection                                                                                                                                              \[[@B33]\]
  *Dysosma versipellis* (Hance) M. Cheng ex Ying                                Bajiaolian         LT                SYNP       ZTL, HJXJC, SLAC, WJHXZTT   LD~50~ is 0.493 ± 0.032 g/kg (mice, p.o.) and is toxic to the heart and central nervous system, appearing excited then inhibited                                                                                         \[[@B55]\]
  *Millettia bonatiana* Pamp.                                                   Dafahan            MT                SYNP       HSTT                        Damages the stomach                                                                                                                                                                                                      \[[@B33]\]
  *Craibiodendron yunnanense* W. W. Smith                                       Jinyezi            HT                SYNP       ZTL                         Unknown                                                                                                                                                                                                                   
  *Tripterygium hypoglaucum* (Levl.) Hutch                                      Huobahuagen        MT                SYNP       ZTL, GFNC                   ---                                                                                                                                                                                                                       
  *Anemone rivularis* Bunch. Ham. ex DC.                                        Wuzhangcao         LT                SYNP       TYGT, YSL                   Unknown                                                                                                                                                                                                                   
  *Delphinium yunnanense* Franch.                                               Daotihu            MT                SGZP       WHXZTC                      Unknown                                                                                                                                                                                                                   
  *Dioscorea bulbifera* L.                                                      Huangyaozi         LT                SGDP       FFLC, FFLG                  LD~50~ is 25.49 g/kg (mice, i.p.), LD~50~ is 79.98 g/kg, 250.3 g/kg, or 544 g/kg (mice, p.o.), toxic target organs including the liver and kidney                                                                        \[[@B56], [@B57]\]
  *Clematis apiifolia* var. *argentilucida* (H. Leveille & Vaniot) W. T. Wang   Shanmutong         LT                SHNP       NQSG                        Unknown                                                                                                                                                                                                                   
  *Anisodus acutangulus* C. Y. Wu et C. Chen                                    Sanfensan          HT                SYNP       TXT                         Unknown                                                                                                                                                                                                                   
  *Datura stramonium* L.                                                        Mantuoluoye        MT                SYNP       YWNC                        Shortness of breath and death after nerve stimulation                                                                                                                                                                    \[[@B33]\]
  *Aconitum brachypodum* Diels.                                                 Xueshangyizhihao   HT                SHNP       ZTL                         LD~50~ are 6766.928 and 5492.337 mg/kg (petroleum ether extracts, N-butanol extracts, mice, p.o.)                                                                                                                        \[[@B58]\]

HT, high toxicity; MT, medium toxicity; LT, low toxicity. ^*∗*^The herb has more than two origins of species, only one origin is shown. SGZP, Standards for Chinese medicinal materials in Guizhou Province (2009); SGDP, Standards for Chinese medicinal materials in Guangdong Province (2011); SHNP, Standards for Chinese medicinal materials in Hunan Province (2009); SYNP, Standards for Chinese medicinal materials in Yunnan Province (2005). GFNC, Gu Feng Ning Capsule; NQSG, Niao Qing Shu Granular; SYA, Shang Yi Aerosol; TSC, Tong Shu Capsule; ZTL, Zhong Tong Liniment; SWYA, Shu Wei Yao Alcohol; GDQC, Gan Dan Qing Capsule; HWYP, Huoxiang Wan Ying Powder; CLTC, Chuan Luo Tong Capsule; KSG, Kang Shen Granular; TXT, Tian Xiang Tincture; KLT, Ke Tan Oral liquid; LL, Lingdancao Oral liquid; SKCG, Shijiaocao Ke Chuan Granular; WFSC, Wei Fu Shu Capsule; ZXASG, Zhi Xuan An Shen Granular; SAC, Shen An Capsule; HJXJC, Hong Jin Xiao Jie Capsule; SLAC, Shu Lie An Capsule; WJHXZTT, Wu Jin Huo Xue Zhi Tong Tablet; HSTT, Huzhang Shang Tong Tincture; GFNC, Gu Feng Ning Capsule; TYGT, Tianhusui Yu Gan Tablet; YSL, Yan Shu Oral liquid; WHXZTC, Wujin Huo Xue Zhi Tong Capsule; FFLC, Fu Fang Luxiancao Capsule; FFLG, Fu Fang Luxiancao Granular; NQSG, Niao Qing Shu Granular; YWNC, Yun Wei Ning Capsule.
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